{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_3144299_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"062-168-612-713-916"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8755,"type":"PATENT","title":"Cambridge University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6660,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8200,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and owners= \"Cambridge Univ\", \" Univ Cambridge\", \" University of Cambridge\", \" Cambridge University\" , \" Cambridge Enterprise Ltd\" , \"cambridge University Technical\", \" Cambridge Univ Entpr Ltd\" , \"cambri* Univ*\"
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 5951
\n","published":true,"created":"2015-11-19T00:30:22Z","updated":"2017-08-07T00:27:53Z","sharedType":"PUBLISHED","collectionId":8755,"collectionTitle":"Cambridge University Patent Portfolio","collectionType":"PATENT"}],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-19T00:30:22Z","updated":"2017-11-16T04:41:56Z","lastEventDate":"2017-11-16T04:41:56Z"},{"id":8876,"type":"PATENT","title":"Northwestern University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17491,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8210,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and Owners separately = \" Northwestern University\", 'Northw* Univ*\" , \"Univ Northwestern\", \"
Searched applicants and owners= \"Cambridge Univ\", \" Univ Cambridge\", \" University of Cambridge\", \" Cambridge University\" , \" Cambridge Enterprise Ltd\" , \"cambridge University Technical\", \" Cambridge Univ Entpr Ltd\" , \"cambri* Univ*\"
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 5951
\n","published":true,"created":"2015-11-19T00:30:22Z","updated":"2017-08-07T00:27:53Z","sharedType":"PUBLISHED","collectionId":8755,"collectionTitle":"Cambridge University Patent Portfolio","collectionType":"PATENT"}],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-19T00:30:22Z","updated":"2017-11-16T04:41:56Z","lastEventDate":"2017-11-16T04:41:56Z"},{"id":8876,"type":"PATENT","title":"Northwestern University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17491,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8210,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and Owners separately = \" Northwestern University\", 'Northw* Univ*\" , \"Univ Northwestern\", \"
L1 is a valence bond or a bivalent optionally substituted saturated, partially saturated, or unsaturated hydrocarbon chain, wherein 1-3 methylene units of L1 are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-, -SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-; or wherein L1 is -(C(R)2)n- and wherein n is 1 to 6, inclusive;
R1 is -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, -N(R)2, or wherein R1 is phenyl, a 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R1 is optionally substituted with p occurrences of Ra, wherein p is 0 to 5, inclusive;
each Ra is independently selected from the group consisting of -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, -N(R)2, or wherein Ra is an optionally substituted 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each R is independently hydrogen, halogen, optionally substituted C1-6 aliphatic, optionally substituted phenyl, optionally substituted benzyl, or two R on the same nitrogen are taken together to form a 5-6 membered saturated, partially saturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
L2 is a valence bond or a bivalent optionally substituted saturated, partially saturated, or unsaturated hydrocarbon chain, wherein 1-3 methylene units of L2 are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-, -SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-; or wherein L2 is -(C(R)2)m- and wherein m is 1 to 6, inclusive;
R2 is -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, -N(R)2, or wherein R2 is phenyl, a 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R2 is optionally substituted with q occurrences of Rb, wherein q is 0 to 5, inclusive;
each Rb is independently selected from the group consisting of -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, -N(R)2, or wherein Rb is an optionally substituted 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R3 and R3 are independently hydrogen, halogen, or optionally substituted C1-6 aliphatic, or R3 and R3' are taken together to form a C1 alkenylene optionally substituted with one or two Rc groups;
each Rc is independently -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, -N(R)2, or wherein Rc is phenyl, a 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein Rc is optionally substituted with t occurrences of Rd, wherein t is 0 to 5, inclusive; and
each Rd is independently -R, -OR, -CN, -C(R)3, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, or -N(R)2."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein L1 is a valence bond, or wherein L1 is a bivalent optionally substituted saturated, partially saturated, or unsaturated hydrocarbon chain, wherein 1-3 methylene units of L1 are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-, -SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-, or wherein L1 is a bivalent, optionally substituted, saturated hydrocarbon chain, wherein 1 methylene unit of L1 is replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-,-SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-, or wherein L1 is a bivalent optionally substituted saturated hydrocarbon chain, wherein 1 methylene unit of L1 is replaced by -NR-, -O-, or -S-, or wherein L1 is a bivalent optionally substituted saturated hydrocarbon chain, wherein 1 methylene unit of L1 is replaced by -O-, or wherein L1 is -(C(R)2)n- and wherein n is 1 to 6, preferably wherein n is 2, 3 or 4; or wherein preferably at least one R is independently halogen; further preferably wherein at least one R is independently fluorine."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein R1 is -R, hydrogen, halogen, -OR,-CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R,-NRC(O)N(R)2, -NRSO2R, or -N(R)2; or wherein R1 is unsubstituted phenyl; or wherein R1 is phenyl optionally substituted with Ra; preferably wherein p is 1, 2, 3, 4, or 5; or preferably wherein (a) at least one Ra is independently halogen, or wherein (b) at least two Ra are independently halogen, or wherein (c) at least one Ra is independently -OR, or wherein (d) at least two Ra are independently -OR, or wherein (e) at least one Ra is independently selected from the group consisting of methyl, ethyl, propyl, or butyl."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein R1 is of the formula: or wherein R1 is selected from: or wherein R1 is selected from: or wherein R1 is selected from: or wherein R1 is selected from: or wherein R1 is of the formula: or wherein R1 is an optionally substituted 5-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is an unsubstituted 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is a substituted 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is optionally substituted thiophene, or wherein R1 is optionally substituted furan, or wherein R1 is an unsubstituted 6-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is a substituted 6-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is an optionally substituted 8-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is an optionally substituted 9-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is an optionally substituted 10-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R1 is R, preferably wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl, or butyl."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein L2 is a valence bond, or wherein L2 is a bivalent optionally substituted saturated, partially saturated, or unsaturated hydrocarbon chain, wherein 1-3 methylene units of L2 are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-, -SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-, or wherein L2 is a bivalent optionally substituted saturated hydrocarbon chain, wherein one methylene unit of L2 is replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO2-, -SO2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -SO2-., or wherein L2 is a bivalent optionally substituted saturated hydrocarbon chain, wherein one methylene unit of L2 is replaced by -NR-, -O-, or -S-, or wherein L2 is a bivalent optionally substituted saturated hydrocarbon chain, wherein one methylene unit of L2 is replaced by -O-, or wherein L2 is -(C(R)2)m- and wherein m is 1 to 6, preferably wherein m is 2, 3 or 4; or preferably wherein at least one R is independently halogen, further preferably wherein at least one R is independently fluorine."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein R2 is -R, -OR, -CN, -NO2, -SR, -S(O)R, -SO2R, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R, or -N(R)2., or wherein R2 is unsubstituted phenyl, or wherein R2 is phenyl optionally substituted with Rb, preferably wherein q is 1, 2, 3, 4 or 5, or wherein at least one Rb is independently halogen, or wherein at least two Rb are independently halogen, or wherein at least one Rb is independently -OR, or wherein at least two Rb are independently -OR, or wherein at least one Rb is independently selected from the group consisting of methyl, ethyl, propyl, or butyl."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein R2 is of the formula: or wherein R2 is selected from: or wherein R2 is selected from: or wherein R2 is selected from: or wherein R2 is selected from: or wherein R2 is of the formula: or wherein R2 is an optionally substituted 5-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is an unsubstituted 5- membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is a substituted 5- membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is optionally substituted thiophene, or wherein R2 is optionally substituted furan, wherein R2 is an unsubstituted 6-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is a substituted 6-membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is an optionally substituted 8-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is an optionally substituted 9-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is an optionally substituted 10-membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or wherein R2 is R, preferably wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl, or butyl."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, wherein at least one of R3 or R3' is hydrogen, or wherein both R3 and R3' are hydrogen, or wherein at least one of R3 or R3' is fluorine, or wherein R3 and R3' are taken together to form a C1 alkenylene optionally substituted with one or two Rc groups, or wherein R3 and R3' are taken together to form a C1 alkenylene optionally substituted with one Rc group."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, of one of the formulae: or of one of the formulae: or of the formula: or of one of the formulae: or of one of the formulae: or of any one of the formulae: or of any one of the formulae: or of the following formula: or of the following formula: preferably wherein at least one Ra is independently a halogen, or wherein at least one Rb is independently a halogen."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 1, of the formula: or of the formula: or of the formula: or of any one of the following formulae: or of any one of the formulae: or of the formula: or of either of the following formulae: or of either of the following formulae: or of either of the following formulae: or of either of the following formulae: or of any one of the following formulae: or of any one of the following formulae: or of any one of the following formulae: or of any one of the following formulae: or of any one of the following formulae:"],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising:
a compound of any one of claims 1 to 10, and a pharmaceutically acceptable excipient, preferably for use in the treatment of a neurodegenerative disease, preferably wherein said disease is ALS."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient for use in the treatment of a disease associated with abnormal protein aggregation."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["Compound of any of claims 1 to 10 for use in the treatment of amyotrophic lateral sclerosis, wherein the severity or incidence of one or more symptoms of ALS is reduced, or its onset is delayed, or compound of any of claims 1 to 10 in an amount sufficient to reduce or delay such abnormal protein aggregation for the treatment of abnormal protein aggregation, preferably wherein the protein aggregates are G93A SOD1 protein aggregates, or wherein the protein aggregates are G85R SOD1 protein aggregates."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 13, wherein the subject of the treatment is a test subject, or wherein the subject is a human, or wherein the subject is an adult human, or wherein the compound is administered in doses of less than about 20 mg/day, or wherein the compound is administered in doses ranging from about 1 mg/kg/day to about 50 mg/kg/day, or wherein the compound is administered in doses ranging from about 1 mg/kg/day to about 40 mg/kg/day, or wherein the compound is administered in doses ranging from about 1 mg/kg/day to about 30 mg/kg/day, or wherein the compound is administered in doses ranging from about 1 mg/kg/day to about 20 mg/kg/day, or wherein the compound is administered in doses ranging from about 1 mg/kg/day to about 10 mg/kg/day, or wherein the compound is administered systemically, preferably wherein the compound is administered intravenously, or wherein the compound is administered intraperitonealy, or wherein the compound is administered orally."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 13, further comprising the step of monitoring the subject, preferably wherein the subject is monitored by monitoring motor function, or wherein the subject is monitored by monitoring body weight, or wherein the subject is monitored by monitoring survival time, or wherein the subject is monitored one, two, three, four, or five times a day, or wherein the subject is monitored one, two, three, four or five times a week, or wherein the subject is monitored twice a week, or wherein said monitoring occurs for the duration of the subject's life, o wherein the subject is monitored three times a day."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method comprising the steps of:
administering to a cell in vitro a therapeutically effective amount of the compound of any of claims 1 to 10 to inhibit or reverse abnormal protein aggregation, or
comprising the steps of:"],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The compound of any one of claims 1 to 10, which compound is in an isolated state, preferably which compound is in a pure state."],"number":17,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}administering to a cell, preferably to a mammalian cell, in vitro an effective amount of the compound of any of claims 1 to 10 to protect against aggregated SOD1, preferably wherein the protein aggregates are G93A SOD1 protein aggregates, or wherein the protein aggregates are G85R SOD1 protein aggregates, or wherein the SOD1 is G93A SOD1, or wherein the SOD1 is G85R SOD1, or a method comprising the steps of:administering to a cell in vitro an effective amount of the compound of any of claims 1 to 10 to modulate proteasome function, preferably wherein the cells are mammalian cells.